BLCO
Bausch + Lomb Corporation
BLCO has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BLCO overall, supported by stronger fundamentals and stronger modeled upside.
BLCO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
BLCO's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BLCO PE Valuation
BLCO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BLCO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BLCO, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BLCO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.17 | — |
| Q3 2026 | -$0.31 | +$0.55 |
| Q2 2026 | -$0.48 | +$0.29 |
| Q1 2026 | -$0.62 | +$0.40 |
| Q4 2025 | -$1.02 | -$0.12 |
| Q3 2025 | -$0.86 | +$0.19 |
| Q2 2025 | -$0.77 | +$0.53 |
| Q1 2025 | -$1.02 | -$0.06 |
| Q4 2024 | -$0.90 | -$0.16 |
BLCO is still losing money, but far less than before: $0.31 per share over the past year, against $1.30 at its worst in mid-2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BLCO on earnings quality, reporting a profit while its opponent remains loss making.
BLCO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +7.3% |
| Q2 2026 | $1.4B | +9.1% |
| Q1 2026 | $1.2B | +9.4% |
| Q4 2025 | $1.4B | +9.8% |
| Q3 2025 | $1.3B | +7.1% |
| Q2 2025 | $1.3B | +5.1% |
| Q1 2025 | $1.1B | +3.5% |
| Q4 2024 | $1.3B | +9.1% |
BLCO's revenue has grown year over year for 15 quarters in a row: $1.4B last quarter, up 7.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | +3.8 points |
| Q2 2026 | 6% | +6.8 points |
| Q1 2026 | 2.6% | +9.9 points |
| Q4 2025 | 8% | +1.2 points |
| Q3 2025 | 7.4% | +3.8 points |
| Q2 2025 | -0.9% | -3 points |
| Q1 2025 | -7.3% | -7.8 points |
| Q4 2024 | 6.8% | +2.6 points |
BLCO has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BLCO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BLCO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $178M | +183% |
| Q2 2026 | $82M | +$136M |
| Q1 2026 | -$68M | +$67M |
| Q4 2025 | $60M | +$130M |
| Q3 2025 | $63M | -33% |
| Q2 2025 | -$54M | +$3M |
| Q1 2025 | -$135M | -$109M |
| Q4 2024 | -$70M | -$1M |
BLCO's free cash flow has turned positive after four years mostly in the red: $252M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BLCO on cash flow, with more consistent year-over-year improvement.
BLCO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +4.4M shares |
| 1 year | +2.1% | +7.3M shares |
| 3 years | +3.1% | +10.7M shares |
| 5 years | +3.3% | +11.5M shares |
| Available history | +3.3% | +11.5M shares |
BLCO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BLCO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.7x | High |
| Q2 2026 | 6.4x | High |
| Q1 2026 | 7.4x | High |
| Q4 2025 | 8.7x | High |
| Q3 2025 | 9.0x | High |
| Q2 2025 | 10.1x | High |
| Q1 2025 | 9.2x | High |
| Q4 2024 | 7.5x | High |
BLCO's net debt is about 5.7 years of its operating earnings (EBITDA), down from 9.0 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over BLCO on leverage, with a lower net debt burden relative to earnings.
BLCO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 73.1 | Overbought |
| Stochastic | 83.1 | Overbought |
BLCO's weekly RSI is 73 (overbought) and its Stochastic is 83 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BLCO PE vs Healthcare Sector
| Metric | BLCO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BLCO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BLCO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.3 | 16% above |
| 20 week MA | $17.5 | 21% above |
| 50 week MA | $16.9 | 25% above |
| 100 week MA | $15.7 | 34% above |
| 200 week MA | $16.4 | 29% above |
BLCO has climbed back above all five of its weekly moving averages, and it's now 29% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
BLCO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $20.0 | $14.6 | -27% |
| 2023 | $14.6 | $17.1 | +17% |
| 2024 | $17.1 | $18.0 | +5.3% |
| 2025 | $18.0 | $17.2 | -4.4% |
| 2026 YTD | $17.2 | $21.1 | +23% |
BLCO has finished lower in two of the last four years. It's up 23% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BLCO on returns for 2026, with the stronger performance.